BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36104354)

  • 1. Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.
    Zhao X; Wang P; Diedrich JD; Smart B; Reyes N; Yoshimura S; Zhang J; Yang W; Barnett K; Xu B; Li Z; Huang X; Yu J; Crews K; Yeoh AEJ; Konopleva M; Wei CL; Pui CH; Savic D; Yang JJ
    Nat Commun; 2022 Sep; 13(1):5401. PubMed ID: 36104354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
    Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
    Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion.
    Shago M; Abla O; Hitzler J; Weitzman S; Abdelhaleem M
    Pediatr Blood Cancer; 2016 Nov; 63(11):1915-21. PubMed ID: 27392123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
    Madero-Marroquin R; DuVall AS; Saygin C; Wang P; Gurbuxani S; Larson RA; Stock W; Patel AA
    Br J Haematol; 2024 Apr; 204(4):1238-1242. PubMed ID: 38073116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells.
    Yaguchi A; Ishibashi T; Terada K; Ueno-Yokohata H; Saito Y; Fujimura J; Shimizu T; Ohki K; Manabe A; Kiyokawa N
    Int J Hematol; 2017 Aug; 106(2):269-281. PubMed ID: 28378055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
    Gutierrez-Camino A; Richer C; Ouimet M; Fuchs C; Langlois S; Khater F; Caron M; Beaulieu P; St-Onge P; Bataille AR; Sinnett D
    Br J Cancer; 2024 Feb; 130(2):317-326. PubMed ID: 38049555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc finger protein 384 (
    Sudutan T; Erbilgin Y; Hatirnaz Ng O; Karaman S; Karakas Z; Kucukcankurt F; Celkan T; Timur C; Ozdemir GN; Hacısalihoglu S; Gelen SA; Sayitoğlu M
    Leuk Lymphoma; 2022 Dec; 63(12):2931-2939. PubMed ID: 35921545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia.
    Hou Z; Ren Y; Zhang X; Huang D; Yan F; Sun W; Zhang W; Zhang Q; Fu X; Lang Z; Chu C; Zou B; Gao B; Jin B; Kang Z; Liu Q; Yan J
    Cell Commun Signal; 2024 Apr; 22(1):211. PubMed ID: 38566191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZNF384 Fusion Oncoproteins Drive Lineage Aberrancy in Acute Leukemia.
    Dickerson KM; Qu C; Gao Q; Iacobucci I; Gu Z; Yoshihara H; Backhaus EA; Chang Y; Janke LJ; Xu B; Wu G; Papachristou EK; D'Santos CS; Roberts KG; Mullighan CG
    Blood Cancer Discov; 2022 May; 3(3):240-263. PubMed ID: 35247902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.
    Hirabayashi S; Ohki K; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yaguchi A; Terada K; Saito Y; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fujimura J; Hino M; Kinoshita A; Kakuda H; Kurosawa H; Kato K; Kajiwara R; Moriwaki K; Morimoto T; Nakamura K; Noguchi Y; Osumi T; Sakashita K; Takita J; Yuza Y; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Fukushima T; Koh K; Manabe A; Ohara A; Kiyokawa N;
    Haematologica; 2017 Jan; 102(1):118-129. PubMed ID: 27634205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.
    Jing Y; Li YF; Wan H; Liu DH
    Ann Hematol; 2020 Nov; 99(11):2611-2617. PubMed ID: 32980888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Schneider P; Meier M; Beverloo HB; Pieters R
    Haematologica; 2007 Nov; 92(11):1565-8. PubMed ID: 18024407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
    Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
    Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel approach for relapsed/refractory FLT3
    Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
    Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZNF384-Related Fusion Genes in Acute Lymphoblastic Leukemia.
    Zhu L; Bai W; Cheng Q; Fang J
    Cancer Control; 2023; 30():10732748231182787. PubMed ID: 37306722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of a Cryptic EP300/ZNF384 Gene Fusion by Chromosomal Microarray and Next-Generation Sequencing Studies in a Pediatric Patient with B-Lymphoblastic Leukemia.
    Berg HE; Blackburn PR; Smadbeck JB; Swanson KE; Rice CS; Webley MR; Johnson SH; Vasmatzis G; Xu X; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Boston CH; Sutton LM; Peterson JF
    Lab Med; 2021 May; 52(3):297-302. PubMed ID: 33145596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking.
    Yang M; Safavi S; Woodward EL; Duployez N; Olsson-Arvidsson L; Ungerbäck J; Sigvardsson M; Zaliova M; Zuna J; Fioretos T; Johansson B; Nord KH; Paulsson K
    Blood; 2020 Aug; 136(8):946-956. PubMed ID: 32384149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities.
    Yamamoto H; Hayakawa F; Yasuda T; Odaira K; Minamikawa Y; Tange N; Hirano D; Kojima Y; Morishita T; Tsuzuki S; Naoe T; Kiyoi H
    FEBS Lett; 2019 Aug; 593(16):2151-2161. PubMed ID: 31234226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.